FDA Kicks Off Opioid Class REMS Discussion; Asks For Industry Collaboration

FDA laid out general guidelines for a class-wide Risk Evaluation and Mitigation Strategy for opioid pain products during a closed-door meeting March 3, and urged manufacturers to work collaboratively to help develop a proposal as soon as possible